|Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer|
CG Willett, Y Boucher, E Di Tomaso, DG Duda, LL Munn, RT Tong, ...
Nature medicine 10 (2), 145-147, 2004
|AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients|
TT Batchelor, AG Sorensen, E di Tomaso, WT Zhang, DG Duda, ...
Cancer cell 11 (1), 83-95, 2007
|Angiogenesis in brain tumours|
RK Jain, E Di Tomaso, DG Duda, JS Loeffler, AG Sorensen, TT Batchelor
Nature Reviews Neuroscience 8 (8), 610-622, 2007
|Normalization of the vasculature for treatment of cancer and other diseases|
S Goel, DG Duda, L Xu, LL Munn, Y Boucher, D Fukumura, RK Jain
Physiological reviews 91 (3), 1071-1121, 2011
|Lessons from phase III clinical trials on anti-VEGF therapy for cancer|
RK Jain, DG Duda, JW Clark, JS Loeffler
Nature clinical practice Oncology 3 (1), 24-40, 2006
|Engineering vascularized tissue|
RK Jain, P Au, J Tam, DG Duda, D Fukumura
Nature biotechnology 23 (7), 821-823, 2005
|Biomarkers of response and resistance to antiangiogenic therapy|
RK Jain, DG Duda, CG Willett, DV Sahani, AX Zhu, JS Loeffler, ...
Nature reviews Clinical oncology 6 (6), 327-338, 2009
|Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy|
Y Huang, J Yuan, E Righi, WS Kamoun, M Ancukiewicz, J Nezivar, ...
Proceedings of the National Academy of Sciences 109 (43), 17561-17566, 2012
|Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study|
CG Willett, DG Duda, E Di Tomaso, Y Boucher, M Ancukiewicz, ...
Journal of Clinical Oncology 27 (18), 3020, 2009
|Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo|
M Stroh, JP Zimmer, DG Duda, TS Levchenko, KS Cohen, EB Brown, ...
Nature medicine 11 (6), 678-682, 2005
|Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study|
AX Zhu, DV Sahani, DG Duda, E Di Tomaso, M Ancukiewicz, ...
Journal of clinical oncology 27 (18), 3027, 2009
|Phase II study of cediranib, an oral pan–vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma|
TT Batchelor, DG Duda, E di Tomaso, M Ancukiewicz, SR Plotkin, ...
Journal of Clinical Oncology 28 (17), 2817, 2010
|Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal …|
CG Willett, Y Boucher, DG Duda, E Di Tomaso, LL Munn, RT Tong, ...
Journal of Clinical Oncology 23 (31), 8136-8139, 2005
|Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges|
D Fukumura, J Kloepper, Z Amoozgar, DG Duda, RK Jain
Nature reviews Clinical oncology 15 (5), 325, 2018
|HCC and angiogenesis: possible targets and future directions|
AX Zhu, DG Duda, DV Sahani, RK Jain
Nature reviews Clinical oncology 8 (5), 292, 2011
|Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre‐clinical models|
DAI Fukumura, DG Duda, LL Munn, RK Jain
Microcirculation 17 (3), 206-225, 2010
|Malignant cells facilitate lung metastasis by bringing their own soil|
DG Duda, AMMJ Duyverman, M Kohno, M Snuderl, EJA Steller, ...
Proceedings of the National Academy of Sciences 107 (50), 21677-21682, 2010
|CXCL12 (SDF1α)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?|
DG Duda, SV Kozin, ND Kirkpatrick, L Xu, D Fukumura, RK Jain
Clinical cancer research 17 (8), 2074-2080, 2011
|Vascular normalization as an emerging strategy to enhance cancer immunotherapy|
Y Huang, S Goel, DG Duda, D Fukumura, RK Jain
Cancer research 73 (10), 2943-2948, 2013
|Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis|
D Fukumura, A Ushiyama, DG Duda, L Xu, J Tam, V Krishna, K Chatterjee, ...
Circulation research 93 (9), e88-e97, 2003